Inbakicept(Inbakicept) - 药物靶点：IL15R_专利_临床

概要

基本信息

药物类型

融合蛋白

别名

Inbakicept (USAN/INN)

靶点

IL15R

作用机制

IL15R激动剂(白细胞介素-15受体激动剂)

治疗领域-

在研适应症-

非在研适应症-

原研机构

Altor BioScience Corp.

在研机构

Altor BioScience Corp.

非在研机构-

最高研发阶段药物发现

首次获批日期-

最高研发阶段(中国)-

特殊审评-

序列信息

Sequence Code 14770950

来源: *****

关联

100 项与 Inbakicept 相关的临床结果

登录后查看更多信息

100 项与 Inbakicept 相关的转化医学

登录后查看更多信息

100 项与 Inbakicept 相关的专利（医药）

登录后查看更多信息

2

项与 Inbakicept 相关的文献（医药）

2024-07-01·Drugs

Nogapendekin alfa Inbakicept: First Approval

Review

作者: Keam, Susan J

Nogapendekin alfa inbakicept (ANKTIVA^®; nogapendekin alfa inbakicept-pmln) is a recombinant interleukin-15 (IL-15) superagonist protein complex being developed by Altor BioScience, LLC, an indirect wholly owned subsidiary of ImmunityBio, Inc., for the treatment of solid and haematological cancers and HIV infection. In April 2024, nogapendekin alfa inbakicept was approved for use with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours in the USA. This article summarizes the milestones in the development of nogapendekin alfa inbakicept leading to this first approval for the treatment of cancer.

Annals of Medicine & Surgery

Nogapendekin alfa inbakicept-PMLN: first approval milestone for BCG-unresponsive noninvasive bladder cancer: editorial